ClinicalTrials.gg

Program

sasanlimab

Also written as “PF-06801591” and “Sasanlimab”.

In Pfizer's pipeline, Anti-PD-1. Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Non-Muscle Invasive Bladder Neoplasms · Melanoma, led by Pfizer.

Furthest: phase 3, since Nov 13, 20194 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer41 open or runningphase 3since Nov 13, 2019Oct 6, 2015none ahead
  • Named in Pfizer’s own pipeline as sasanlimab PF-06801591, phase 3, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 6, 2015First study: phase 1 study in MelanomaFirst studyNCT02573259 · 147 enrolled · United States, Bulgaria, Korea, Republic of and more
  2. Nov 13, 2019Phase 3 study in Non-Muscle Invasive Bladder NeoplasmsNCT04165317 · 1,068 enrolled · United States, Australia, Belgium and more
  3. Nov 14, 2019Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04181788 · 155 enrolled · China, Japan, Russia and more
  4. Sep 30, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04585815 · 34 enrolled · United States, Australia, Belgium and more

TargetBeta

“Anti-PD-1”the company's pipeline, read by Claude · source
“An inhibitor of the human inhibitory receptor programmed cell death 1 (PD-1; PDCD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sasanlimab targets and binds to PD-1 and blocks the interaction between PD-1 and its ligands, PD-1 ligand 1 (PD-L1) …”NCIt, read by Claude

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04585815Carcinoma, Non-Small-Cell Lung · United States, Australia, Belgium and more2TerminatedMay 17, 202334
NCT04181788Carcinoma, Non-Small-Cell Lung · China, Japan, Russia and more2CompletedMar 3, 2022155
NCT04165317Non-Muscle Invasive Bladder Neoplasms · United States, Australia, Belgium and more3Active, not recruitingDec 2, 20241,068
NCT02573259Melanoma · United States, Bulgaria, Korea, Republic of and more1CompletedNov 19, 2020147

How it is read

Names in the registry

  • “PF-06801591”, 4 entries
  • “Sasanlimab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.